- ￥1090 - 1590
- CUSABIO
- 武汉
- CSB-PA000734
- 2025年07月11日
- ELISA, WB, IHC, IF
- Rabbit
- Human, Mouse, Rat
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Synthesized peptide derived from Human IGF-IR around the phosphorylation site of Y1161.
- 亚型：
IgG
- 形态：
Liquid
- 保存条件：
-20°C
- 克隆性：
多克隆
- 标记物：
Non-conjugated
- 适应物种：
Human, Mouse, Rat
- 保质期：
12个月
- 抗原来源：
Human
- 目录编号：
CSB-PA000734
- 级别：
多克隆抗体
- 库存：
充足
- 供应商：
武汉益普生物科技有限公司
- 宿主：
Rabbit
- 应用范围：
ELISA, WB, IHC, IF
- 靶点：
IGF1R/INSR
- 抗体英文名：
Phospho-IGF1R/INSR (Y1161) Antibody
- 规格：
50μg/100μg
| 规格： | 50μg | 产品价格： | ￥1090.0 |
|---|---|---|---|
| 规格： | 100μg | 产品价格： | ￥1590.0 |
| 产品名称 | Phospho-IGF1R/INSR (Y1161) Antibody |
| 货号 | CSB-PA000734 |
| 别名 | IGF1R; Insulin-like growth factor 1 receptor; Insulin-like growth factor I receptor; IGF-I receptor; CD antigen CD221; INSR; Insulin receptor; IR; CD antigen CD220 |
| 抗体类型 | Polyclonal Antibody |
| 克隆类型 | Polyclonal |
| Uniprot No. | P08069/P06213 |
| 基因名 | IGF1R/INSR |
| 免疫原种属 | Human |
| 免疫原 | Synthesized peptide derived from Human IGF-IR around the phosphorylation site of Y1161. |
| 宿主 | Rabbit |
| 反应种属 | Human, Mouse, Rat |
| 应用范围 | ELISA, WB, IHC, IF |
| 抗体亚型 | IgG |
| 标记方式 | Non-conjugated |
| 产品提供形式 | Liquid |
| 纯化方式 | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| 研究领域 | Signal Transduction |
| 保存缓冲液 | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| 储存条件 | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验IMMUNOSCREENING OF WITH ANTIBODY PROBES
Adsroption of Anti-E. coli Antibodies Grow E. coli strain Y1090 in L broth at 37°C overnight. Transfer to 10 mM MgSO4 and store at 4°C for future use. These cells are good for about 1 week. Soak one 132 mm nitrocellulose membrane per Petri dish
Radiometal Labeling of Antibodies and Antibody Fragments for Imaging and Therapy
Monoclonal antibodies (MAbs) are highly selective agents for delivering radiation to tumors both for in vivo imaging (radioimmunoscintigraphy, RIS) and for therapy (radioimmunotherapy, RIT). Antibody-based radiopharmaceuticals can be labeled
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
技术资料暂无技术资料 索取技术资料
